David A. Scheinberg, MD, PhD

Dr. Scheinberg is a physician-scientist who specializes in the care of patients with leukemia and is also investigating new therapeutic approaches to cancer, both in the clinic and in the laboratory. His research is focused on discovering and developing novel, specific immunotherapeutic agents. These include monoclonal antibodies that target the cell surface of cancers, targeted radiopharmaceuticals that deliver radioactive particles including alpha particles or alpha particle nanogenerators, targeted nanodevices that selectively kill cancer cells, and therapeutic vaccines that target the oncogene products that cause the cancers.

Eight different therapeutic agents developed by Dr. Scheinberg in his laboratory have reached human clinical trials, including the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, and the first tumor-specific fusion oncogene product vaccines. His laboratory is also investigating cellular resistance mechanisms to these agents. Dr. Scheinberg has published more than 250 papers, chapters, and books in these fields.